While the predictive role of HRD score for PARP inhibitor in uterine carcinosarcoma remains unclear, PARP inhibitor does warrant further therapeutic exploration for TP53-mutated (copy number-high) molecular type of uterine carcinosarcoma. This evidence concerns the gene TP53 and uterine carcinosarcoma.